MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Clinical Oncology' source. Sat, 20 Mar 2010 15:16:58 +0100 http://www.medworm.com/index.php?rid=3234147&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655510000324%2Fabstract%3Frss%3Dyes (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3234147 Wed, 03 Feb 2010 15:36:35 +0100 3234147 http://www.medworm.com/index.php?rid=3234146&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003252%2Fabstract%3Frss%3Dyes Sir — A 49-year-old premenopausal female patient presented with a breast lump and abdominal distention. Her personal history was unremarkable and a family history revealed ovarian cancer in her aunt and thyroid cancer in her brother. On physical examination, a 4cm mass in her right breast and an axillary fixed lymphadenopathy of 2cm were palpated and ascites was detected. Biopsy from the breast lump showed pleomorphic lobular carcinoma, grade 3, oestrogen receptor and progesterone receptor were both positive with HER2 overexpression immunohistochemically. Abdominal computed tomography revealed peritoneal carcinomatosis, ascites and a 15mm left ovarian cyst. A chest X-ray and a bone scan were normal. Diagnostic paracentesis was carried out to rule out a second intra-abdominal malignancy a... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3234146 Wed, 03 Feb 2010 15:36:35 +0100 3234146 http://www.medworm.com/index.php?rid=3234145&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509004105%2Fabstract%3Frss%3Dyes Sir — I read with interest the review by Williams and Drinkwater on radiotherapy in England in 2007. There are many similarities between this report and the review of Australian facilities between 1986 and 1999 . Of particular interest is the low ‘access rates’ of 37% rather than 50%. This is very similar to the Australian results in which the proportion of newly diagnosed patients with invasive non-skin cancers treated with megavoltage therapy was described for each state and for Australia as a whole. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3234145 Wed, 03 Feb 2010 15:36:35 +0100 3234145 http://www.medworm.com/index.php?rid=3234144&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665550900377X%2Fabstract%3Frss%3Dyes Abstract: Aims: Neurological deficit from malignant spinal cord compression (SCC) is a major complication of metastatic castration-resistant prostate cancer (CRPC). The aims of the present study were to determine the incidence of neurological deficit in metastatic prostate cancer patients and to determine the optimal frequency of screening magnetic resonance imaging (MRI) spine required to detect clinically occult radiological SCC (rSCC).Materials and methods: A retrospective analysis of the clinical data of 130 consecutive patients with CRPC, with no functional neurological deficit, who had screening MRI spine from January 2001 to May 2005, was undertaken. Patients found to have rSCC received radiotherapy. All patients were followed-up to document the incidence of neurological deficit.Res... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3234144 Wed, 03 Feb 2010 15:36:35 +0100 3234144 http://www.medworm.com/index.php?rid=3234143&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003768%2Fabstract%3Frss%3Dyes Conclusions: Adjuvant hysterectomy after unsuccessful ICBT does not seem to increase late toxicity and reduces the risk of pelvic recurrence and may improve survival. The role of adjuvant hysterectomy after suboptimal chemoradiation merits further investigation in clinical trials. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3234143 Wed, 03 Feb 2010 15:36:34 +0100 3234143 http://www.medworm.com/index.php?rid=3234142&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655510000051%2Fabstract%3Frss%3Dyes Conclusions: A second admission for radioiodine could have been avoided in most patients. Instead, information from stimulated thyroglobulin and a diagnostic radioiodine scan would have been sufficient to guide further management. This study also provides interesting outcome data on incompletely resected DTC. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3234142 Wed, 03 Feb 2010 15:36:34 +0100 3234142 http://www.medworm.com/index.php?rid=3234141&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003756%2Fabstract%3Frss%3Dyes Abstract: Patients with good prognosis differentiated thyroid cancer are at risk from over-treatment with radioiodine thyroid remnant ablation. Some with unfavourable localised disease might benefit from an elective second dose. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3234141 Wed, 03 Feb 2010 15:36:34 +0100 3234141 http://www.medworm.com/index.php?rid=3234140&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003318%2Fabstract%3Frss%3Dyes Conclusion: This modelling suggests a small therapeutic gain for the use of synchronous chemotherapy instead of radiotherapy dose escalation. This conclusion is dependent on the linear quadratic model and takes no account of late side-effects. This gain would be greater for agents that enhance the mucosal reaction to a lesser degree. This gain may be less when data for radiotherapy dose escalation to smaller high dose volumes using intensity-modulated radiotherapy are considered. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3234140 Wed, 03 Feb 2010 15:36:34 +0100 3234140 http://www.medworm.com/index.php?rid=3234139&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003707%2Fabstract%3Frss%3Dyes Discussion: This hypofractionated regimen is convenient for this patient population and produced comparable outcomes to longer fractionation schedules without an increase in late toxicity. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3234139 Wed, 03 Feb 2010 15:36:34 +0100 3234139 http://www.medworm.com/index.php?rid=3234138&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003744%2Fabstract%3Frss%3Dyes Conclusions: Most of the clinicians followed up their patients up to a minimum of 5 years, with a significant minority who followed up the patients treated for cancers of the head and neck for longer periods. More studies are needed to elucidate the rationale and evidence for follow-up and to determine the adequate period of surveillance. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3234138 Wed, 03 Feb 2010 15:36:34 +0100 3234138 http://www.medworm.com/index.php?rid=3234137&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509004075%2Fabstract%3Frss%3Dyes Abstract: Aims: Most patients with advanced gastroesophageal cancer are elderly, but current standard regimens have emerged from trials predominantly involving patients with a median age (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3234137 Wed, 03 Feb 2010 15:36:34 +0100 3234137 http://www.medworm.com/index.php?rid=3234136&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003288%2Fabstract%3Frss%3Dyes Conclusions: Although there is significant variation in practice patterns and attitudes among radiation oncologists regarding post-lumpectomy radiotherapy for elderly, low-risk breast cancer patients, the vast majority value patient choice and would be willing to use a decision aid designed for this population in their practice. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3234136 Wed, 03 Feb 2010 15:36:34 +0100 3234136 http://www.medworm.com/index.php?rid=3234135&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003781%2Fabstract%3Frss%3Dyes Conclusions: A significant number of interventions were undertaken from the clinic. A large proportion of these could be co-ordinated from primary care, if adequate guidelines are in place. However, rapid advances in breast cancer management should be considered, and cost-effectiveness needs to be studied before making strong recommendations as to where breast cancer follow-up is best managed. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3234135 Wed, 03 Feb 2010 15:36:34 +0100 3234135 http://www.medworm.com/index.php?rid=3147853&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665550900404X%2Fabstract%3Frss%3Dyes (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3147853 Thu, 07 Jan 2010 15:15:22 +0100 3147853 http://www.medworm.com/index.php?rid=3147852&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003720%2Fabstract%3Frss%3Dyes Sir — Adjuvant therapy in early breast cancer reduces the risk of recurrence and death , but the process of adjuvant therapy decision making by multidisciplinary teams (MDTs) varies; some use prognostic indices, such as the Nottingham Prognostic Index, whereas many others do not . There are now different tools and ‘decision aids’ to help the decision making process , such as Adjuvant! Online (www.adjuvantonline.com). The National Institute for Health and Clinical Excellence (NICE) in the UK recommends using Adjuvant! Online in adjuvant therapy decision making . (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3147852 Thu, 07 Jan 2010 15:15:22 +0100 3147852 http://www.medworm.com/index.php?rid=3147851&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003719%2Fabstract%3Frss%3Dyes Sir — We conducted a questionnaire to investigate the use of mobile phones within our department and, in particular, to identify whether staff were incurring personal costs or being contacted outside working hours. A questionnaire was sent to consultants, registrars and clinical nurse specialists. A comparison was made with a similar survey conducted in 2006. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3147851 Thu, 07 Jan 2010 15:15:22 +0100 3147851 http://www.medworm.com/index.php?rid=3147850&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003690%2Fabstract%3Frss%3Dyes We present a patient with sickle cell beta-thalassaemia trait who developed crises with capecitabine chemotherapy. A 55-year-old man with sickle cell beta-thalassemia trait experienced generalised pains and twice a year severe back pains related to his sickle cell. He was diagnosed with Duke's C adenocarcinoma of the sigmoid colon and started adjuvant capecitabine (2300mg twice a day for 14 days every 3 weeks). Fourteen days later he developed severe back pain and was admitted, but a magnetic resonance imaging scan of his spine was normal. His pain settled with analgesia and he was discharged. Cycle 2 proceeded at full dose, but on day 11 he had generalised joint pains and was advised to stop the chemotherapy. The pharmaceutical company was contacted, but they were unable to confirm an as... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3147850 Thu, 07 Jan 2010 15:15:22 +0100 3147850 http://www.medworm.com/index.php?rid=3147849&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003276%2Fabstract%3Frss%3Dyes Sir — We read with great interest the recent papers of Mitry et al. and Nordlinger et al. related to the role of adjuvant chemotherapy in patients with liver metastases from colorectal cancer treated with radical surgery (). (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3147849 Thu, 07 Jan 2010 15:15:22 +0100 3147849 http://www.medworm.com/index.php?rid=3147848&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002696%2Fabstract%3Frss%3Dyes Sir — We read the study by Venkitaraman et al. in which they concluded that triple-negative breast cancers exhibit an elevated risk and an earlier occurrence of brain metastases. They suggested several reasons for a higher propensity for brain metastases in triple-negative breast cancer patients. We want to add another reason. A recent study by Bos et al. looked at the genes that mediate breast cancer metastasis to the brain. They identified the cyclooxygenase COX2, the epidermal growth factor receptor (EGFR) ligand HBEGF, and the alpha2,6-sialyltransferase ST6GALNAC5 as mediators of cancer cell passage through the blood–brain barrier. Furthermore, one of the pivotal studies on basal-like breast cancer showed that EGFR expression is one of the surrogate markers for a specific definit... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3147848 Thu, 07 Jan 2010 15:15:22 +0100 3147848 http://www.medworm.com/index.php?rid=3147847&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003306%2Fabstract%3Frss%3Dyes In conclusion, the evidence base for therapeutic and preventative strategies in treating chronic radiation enteritis is limited, but adopting a structured approach to investigating gastrointestinal symptoms after radiotherapy should allow better targeting of current therapies. Closer collaboration between oncologists and gastroenterologists will facilitate a more structured approach, not only in managing individual patients, but also in establishing clinical and research networks for this expanding disease, in order to improve the evidence base for its management. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3147847 Thu, 07 Jan 2010 15:15:21 +0100 3147847 http://www.medworm.com/index.php?rid=3147846&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002660%2Fabstract%3Frss%3Dyes Abstract: Aims: To evaluate models predicting short survival in patients with brain metastases treated with whole-brain radiotherapy (WBRT).Materials and methods: This was a retrospective analysis of 312 patients. Each patient was assigned to three different four-tiered prognostic scores: the Basic Score for Brain Metastases (BSBM), the Graded Prognostic Assessment (GPA) and the score developed by Rades et al. In addition, a ‘triple-negative’ cohort was evaluated (all three scores predicted unfavourable prognosis, n=30).Results: No statistically significant survival differences were found between the most unfavourable BSBM, GPA, Rades et al. and ‘triple-negative’ groups. The BSBM best predicted short survival: patients classified in the unfavourable group (Karnofsky performance s... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3147846 Thu, 07 Jan 2010 15:15:21 +0100 3147846 http://www.medworm.com/index.php?rid=3147845&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003732%2Fabstract%3Frss%3Dyes Conclusion: Palliative radiotherapy is optimally recommended as the first course of radiotherapy in 14% of all newly diagnosed cancers. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3147845 Thu, 07 Jan 2010 15:15:21 +0100 3147845 http://www.medworm.com/index.php?rid=3147844&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003689%2Fabstract%3Frss%3Dyes Abstract: A substantial proportion of patients who have undergone a radical prostatectomy for localised prostate cancer will have either persistently detectable prostate-specific antigen (PSA) levels or a delayed rise in PSA. The optimum treatment for these situations is not known. The key question is whether the PSA is reflective of local or distant progression. For salvage radiotherapy to be most effective, treatment should be considered before the PSA level is allowed to rise too high, when disease is more likely to be confined to the prostate bed. However, at low PSA levels, current imaging techniques are poor at detecting disease, making it difficult to differentiate local and distant recurrences and to target the radiotherapy appropriately. We review current and investigational imagi... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3147844 Thu, 07 Jan 2010 15:15:21 +0100 3147844 http://www.medworm.com/index.php?rid=3147843&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003264%2Fabstract%3Frss%3Dyes Conclusions: This survey showed that there is a wide variation of practices among radiation oncologists in Canada. These results support the need for treatment guidelines and provide guidance on which factors should be included in a decision-making algorithm. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3147843 Thu, 07 Jan 2010 15:15:21 +0100 3147843 http://www.medworm.com/index.php?rid=3147842&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002738%2Fabstract%3Frss%3Dyes After complete microscopic resection of primary tumour in women with early breast cancer, most local tumour relapses present close to the primary tumour . It is therefore important to ensure that the tumour bed lies well inside the treatment volume encompassed by tangential fields to the whole breast and subsequent tumour bed boost. The penalty for geographical miss is severe: four local tumour relapses cause, on average, one death from breast cancer . The optimal margin to add to the excision cavity for whole breast radiotherapy and the tumour bed boost remains controversial, but there is general agreement that the excision cavity itself must always lie inside the high dose envelope. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3147842 Thu, 07 Jan 2010 15:15:21 +0100 3147842 http://www.medworm.com/index.php?rid=3147841&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003240%2Fabstract%3Frss%3Dyes Conclusions: In this UK network, about half of patients were considered for chemoradiation, but only 18% received it. Survival and treatment-related toxicity are consistent with data from other chemoradiation trials and in our series chemoradiation was tolerated better than chemotherapy alone. This supports the view that ‘consolidation’ chemoradiation is a viable treatment option that should be considered in selected patients with locally advanced non-metastatic pancreatic cancer. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3147841 Thu, 07 Jan 2010 15:15:21 +0100 3147841 http://www.medworm.com/index.php?rid=3147840&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003045%2Fabstract%3Frss%3Dyes In conclusion, patients with CS I NSTC should be assessed and managed at multidisciplinary centres by health care professionals experienced in the treatment of testicular cancer. On the basis of the available evidence, the Genitourinary Disease Site Group recommended primary surveillance for all patients with CS I NSTC, with treatment if relapse occurs. As cancer cure rates are similar with primary surveillance, adjuvant chemotherapy and retroperitoneal lymphadenectomy, patient preference with respect to the risk of recurrence and the timing and toxicities of treatment must be considered. For patients who prefer immediate treatment, or who are unsuitable for primary surveillance, adjuvant chemotherapy with two cycles of bleomycin, etoposide (500mg/m2/cycle) and cisplatin was recommended. S... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3147840 Thu, 07 Jan 2010 15:15:21 +0100 3147840 http://www.medworm.com/index.php?rid=3147839&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002635%2Fabstract%3Frss%3Dyes In conclusion, to date, the optimal management of stage I seminoma remains to be defined. Surveillance seems to be the preferable option, as this strategy minimises the toxicity that might be associated with adjuvant treatment, while preserving high long-term cure rates. The currently available evidence should be presented to patients in order to select the most appropriate option for the individual. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3147839 Thu, 07 Jan 2010 15:15:21 +0100 3147839 http://www.medworm.com/index.php?rid=3147838&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002659%2Fabstract%3Frss%3Dyes Stage I germ cell tumours (tumours that appear clinically to be restricted to the testis) are an oncology success story. As confirmed by the meta-analyses reported in the Cancer Care Ontario guidelines , nearly all patients are cured of their cancer, with most series reporting cure rates of over 98%. As diagnoses are being made earlier, and patients tending to present with earlier disease, at least in the UK, the overall prognosis of germ cell tumours has accordingly improved. The latest UK figures suggest that 97.5% of patients now survive 5 years . These results are a cause for celebration, yet this is not necessarily the end of the story. As we celebrate winning the cancer battle, increasingly we are worrying about losing the long-term war. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3147838 Thu, 07 Jan 2010 15:15:21 +0100 3147838 http://www.medworm.com/index.php?rid=2972981&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003665%2Fabstract%3Frss%3Dyes (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2972981 Mon, 09 Nov 2009 15:31:43 +0100 2972981 http://www.medworm.com/index.php?rid=2972980&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003410%2Fabstract%3Frss%3Dyes Aim/introduction: Sunitinib has been approved by NICE and is recommended as a first-line treatment option for people with advanced and/or metastatic renal cell carcinoma. This recommendation was based on the findings of Motzer et al. In addition to demonstrating improved survival for sunitinib as compared with interferon-alpha, this study also revealed moderate side-effects and the requirement for dose modification. Although treatment is delivered over 6 weekly cycles, we postulate more frequent monitoring is required to maintain patients on therapy. The aim of this study was to evaluate the toxicities and outcomes of treatment with sunitinib in advanced/metastatic renal cell carcinoma. The role of mid-cycle assessment will be determined. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2972980 Mon, 09 Nov 2009 15:31:43 +0100 2972980 http://www.medworm.com/index.php?rid=2972979&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003409%2Fabstract%3Frss%3Dyes Aim/introduction: Prostate cancer is the most commonly diagnosed male cancer in the UK; one third of all new cases present with locally advanced disease. At UCLH, high risk patients deemed to benefit from dose escalation have been treated with combined EBRT and HDR brachytherapy boost since 2000. We revisited 32 of these patients to assess late bowel and bladder toxicity, survival, biochemical relapse and metastatic disease rates. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2972979 Mon, 09 Nov 2009 15:31:43 +0100 2972979 http://www.medworm.com/index.php?rid=2972978&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003392%2Fabstract%3Frss%3Dyes Aim/introduction: Previous studies have shown the activity of metronomic cyclophosphamide-based chemotherapy regimens in the treatment of docetaxel naive, castration refractory prostate cancer [1]. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2972978 Mon, 09 Nov 2009 15:31:43 +0100 2972978 http://www.medworm.com/index.php?rid=2972977&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003380%2Fabstract%3Frss%3Dyes Aim/introduction: The association between androgen deprivation therapy (ADT) for prostate cancer and metabolic syndrome has been reported, with insulin resistance as the key to its development. This is the first study to investigate the effect of metformin and lifestyle changes on the development of ADT-related metabolic syndrome. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2972977 Mon, 09 Nov 2009 15:31:43 +0100 2972977 http://www.medworm.com/index.php?rid=2972976&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003379%2Fabstract%3Frss%3Dyes Aim/introduction: To assess the safety, efficacy and toxicity of higher dose single-agent carboplatin chemotherapy (AUC10) in the treatment of metastatic seminoma, in order to maintain/improve efficacy whilst achieving minimal toxicity. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2972976 Mon, 09 Nov 2009 15:31:43 +0100 2972976 http://www.medworm.com/index.php?rid=2972975&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003367%2Fabstract%3Frss%3Dyes We present the outcome of dose escalation treatment using high dose rate brachytherapy in combination with whole pelvic external beam radiotherapy in the treatment of locally advanced prostate cancer, in our centre. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2972975 Mon, 09 Nov 2009 15:31:43 +0100 2972975 http://www.medworm.com/index.php?rid=2972974&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003355%2Fabstract%3Frss%3Dyes Aim/introduction: Neoadjuvant chemotherapy in muscle-invasive bladder cancer has demonstrated a 5% improvement in absolute overall survival (OS) at 5 years. This retrospective study addressed the tolerance and response to this approach. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2972974 Mon, 09 Nov 2009 15:31:43 +0100 2972974 http://www.medworm.com/index.php?rid=2972973&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003343%2Fabstract%3Frss%3Dyes We report a 5 year experience of real time brachytherapy in large (LP) and standard prostates (SP). (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2972973 Mon, 09 Nov 2009 15:31:43 +0100 2972973 http://www.medworm.com/index.php?rid=2972972&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003331%2Fabstract%3Frss%3Dyes Aim/introduction: This single institution study compared epirubicin/carboplatin/5-fluorouracil (E-Carbo-F) as second-line chemotherapy after docetaxel with docetaxel after E-Carbo-F in castration resistant prostate cancer (CRPC). (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2972972 Mon, 09 Nov 2009 15:31:43 +0100 2972972 http://www.medworm.com/index.php?rid=2972971&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665550900332X%2Fabstract%3Frss%3Dyes We report our experience of a single HDR fraction. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2972971 Mon, 09 Nov 2009 15:31:43 +0100 2972971 http://www.medworm.com/index.php?rid=2972970&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002775%2Fabstract%3Frss%3Dyes 9–10 October 2009 Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2972970 Mon, 09 Nov 2009 15:31:43 +0100 2972970 http://www.medworm.com/index.php?rid=2972969&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003203%2Fabstract%3Frss%3Dyes In a recent paper by Mangar et al. examining the interfractional changes in volume and position during bladder radiotherapy using an empty bladder protocol, it was suggested that reducing the internal margin of the planning target volume (PTV) to 1cm was feasible. An editorial by Lalondrelle and Huddart also discussed the use of smaller margins around the bladder to reduce toxicity. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2972969 Mon, 09 Nov 2009 15:31:42 +0100 2972969 http://www.medworm.com/index.php?rid=2972968&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002684%2Fabstract%3Frss%3Dyes Sir — We were interested to read the paper by Dhadda et al. on optimising the timing of surgical resection of rectal cancer after long-course radiotherapy (LCRT) by calculating ‘volume-halving times’. In their series of 106 patients, they noted that the median tumour volume was 54cm3 and the median tumour-halving time was 14 days (i.e. 10 volume-halving times, 140 days), such that an interval of 20 weeks after the start of radiotherapy would be required to achieve tumour regression to (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2972968 Mon, 09 Nov 2009 15:31:42 +0100 2972968 http://www.medworm.com/index.php?rid=2972967&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002027%2Fabstract%3Frss%3Dyes Brain metastases from colorectal cancer are uncommon, with various studies reporting their development in between 0.3 and 9% of patients . However, over the last 20 years the development of more effective systemic therapies for colorectal cancer, both chemotherapies and biological agents, has altered the natural history of the disease, and the incidence of secondary brain metastases is increasing . The prognosis of patients with colorectal cancer brain metastases is poor, with a median survival of 5.1 months . (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2972967 Mon, 09 Nov 2009 15:31:42 +0100 2972967 http://www.medworm.com/index.php?rid=2972966&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003215%2Fabstract%3Frss%3Dyes Abstract: Aims: To investigate the relationship between the maximum grade of skin toxicity, radiation dose and clinical variables in children receiving treatment for sarcomas involving the bone and soft tissue.Materials and methods: Between January 2003 and July 2006, 82 patients with musculoskeletal tumours on an Institutional Review Board (IRB)-approved prospective study at St. Jude Children's Research Hospital received three-dimensional conformal or intensity-modulated radiation therapy for local tumour control. Radiation dermatitis was graded according to the National Cancer Institute's Common Toxicity Criteria version 2.0 during and after radiation therapy. The dose to the skin was calculated for each patient from the radiation treatment plan.Results: The radiation doses delivered to ... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2972966 Mon, 09 Nov 2009 15:31:42 +0100 2972966 http://www.medworm.com/index.php?rid=2972965&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002714%2Fabstract%3Frss%3Dyes Conclusion: Aggressive fibromatosis is effectively treated with surgery and postoperative radiotherapy. Patients first presenting with tumour recurrence may still have local tumour control comparable with newly diagnosed patients. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2972965 Mon, 09 Nov 2009 15:31:42 +0100 2972965 http://www.medworm.com/index.php?rid=2972964&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002763%2Fabstract%3Frss%3Dyes Conclusion: No effect was seen of either treatment protocols or HPV type on survival, except for a slightly high survival in HPV 58 single-infected patients, which was statistically non-significant. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2972964 Mon, 09 Nov 2009 15:31:42 +0100 2972964 http://www.medworm.com/index.php?rid=2972963&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665550900274X%2Fabstract%3Frss%3Dyes Conclusions: No statistically significant relationship between rectal distension on planning computed tomography and the intra- and interfraction stability of the prostate gland was identified if patients with a large rectal volume were rescanned for planning. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2972963 Mon, 09 Nov 2009 15:31:42 +0100 2972963 http://www.medworm.com/index.php?rid=2972962&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509003227%2Fabstract%3Frss%3Dyes Conclusion: Population-based incidences of SMD requiring local treatment have been reported for the first time. The prevalence of MSCC at the time of cancer diagnosis was higher than previously reported. A more precise definition of MSCC and more population-based studies are needed to reduce selection bias when comparing different studies. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2972962 Mon, 09 Nov 2009 15:31:42 +0100 2972962 http://www.medworm.com/index.php?rid=2972961&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002726%2Fabstract%3Frss%3Dyes Conclusions: Our cohort of patients had an overall local control and survival similar to those documented from other departments. Grade was an important prognostic factor. Patients treated with >50Gy had worse local control outcomes, probably due to selection bias. Dose escalation may still be appropriate for high-risk disease, and may be more effective with more conformal techniques, such as intensity-modulated radiotherapy. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2972961 Mon, 09 Nov 2009 15:31:41 +0100 2972961 http://www.medworm.com/index.php?rid=2972960&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002751%2Fabstract%3Frss%3Dyes We present a review of published studies describing and reporting xerostomia and discuss advances made in the prevention and treatment of this common toxicity. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2972960 Mon, 09 Nov 2009 15:31:41 +0100 2972960 http://www.medworm.com/index.php?rid=2860915&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665550900301X%2Fabstract%3Frss%3Dyes (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2860915 Mon, 05 Oct 2009 17:38:47 +0100 2860915 http://www.medworm.com/index.php?rid=2860914&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002015%2Fabstract%3Frss%3Dyes Sir — Anonymous questionnaire survey forms were posted to 201 breast oncologists in 38 cancer networks across the UK in July 2008. Ninety-six oncologists (48%) from 35 networks (92%) responded (1–12 oncologists/network: median=2; 1–4 oncologists/hospital: median=1). For a 55-year-old fit and well woman, uses of anthracycline (no taxane) and taxane chemotherapy were 95% vs 3% for pN0, 50% vs 50% for pN1 and 9% vs 91% for pN2-3. Nine oncologists from seven networks used only anthracycline chemotherapy (no taxane) for any nodal status. Some oncologists also looked at tumour grade and oestrogen receptor status to make their choices. Different anthracycline regimens were FEC (47%), E-CMF (43%) and EC (9%); different taxane regimens were FEC-D (PACS-01 regime ) (72%), TAC (11%) and others ... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2860914 Mon, 05 Oct 2009 17:38:47 +0100 2860914 http://www.medworm.com/index.php?rid=2860913&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002003%2Fabstract%3Frss%3Dyes Sir — The recent UK National Confidential Enquiry into Patient Outcome and Death (NCEPOD) report, For better, for worse, examined the care of patients who died within 30 days of receiving systemic anticancer treatment (SACT) . This has stimulated debate around concepts such as an ‘acute oncology service’ designed to address key findings in the report. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2860913 Mon, 05 Oct 2009 17:38:47 +0100 2860913 http://www.medworm.com/index.php?rid=2860912&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665550900199X%2Fabstract%3Frss%3Dyes Sir — Temsirolimus has been proven to improve overall survival in poor prognosis patients with metastatic renal cell cancer compared with interferon alpha or interferon alpha plus temsirolimus and prolonged responses to treatment have previously been documented . We would like to report the first case of tumour flare during interruption of treatment of metastatic renal cell carcinoma with temsirolimus. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2860912 Mon, 05 Oct 2009 17:38:47 +0100 2860912 http://www.medworm.com/index.php?rid=2860911&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001988%2Fabstract%3Frss%3Dyes Sir — We congratulate Brock et al. on their timely review of hypofractionated small volume radiotherapy for early-stage non-small cell lung cancer (NSCLC). This letter represents the view of the UK Stereotactic Body Radiotherapy (SBRT) Consortium, which was established in January 2006, and currently includes 21 centres. The consortium has been reviewing published studies on lung SBRT, assessing the technologies available in member departments and working towards developing a set of voluntary recommendations intended to facilitate the controlled introduction of SBRT for early-stage, peripheral NSCLC into the clinic. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2860911 Mon, 05 Oct 2009 17:38:47 +0100 2860911 http://www.medworm.com/index.php?rid=2860910&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001952%2Fabstract%3Frss%3Dyes The National Confidential Enquiry into Patient Outcome and Death (NCEPOD) 2008 report recognised the importance of 30-day mortality for patients receiving systemic anticancer therapy (SACT) . Overall, 2.2% of patients receiving SACT died within 30 days, although site-specific data were not available. It was advised that all deaths within this timeframe should be considered at mortality/morbidity or clinical governance meetings. After this recommendation, the uro-oncology team at The Christie presented their SACT 30-day mortality data for the period of January–December 2008. During this time, 230 patients with genitourinary malignancies were treated with chemotherapy. The rationale for treatment, performance status, grade 3/4 toxicities and certified cause of death were of particular inte... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2860910 Mon, 05 Oct 2009 17:38:46 +0100 2860910 http://www.medworm.com/index.php?rid=2860909&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001940%2Fabstract%3Frss%3Dyes Sir — Brain metastasis from primary breast cancer is a frequent clinical dilemma with few effective therapeutic options. We undertook a study to characterise the receptor profile of breast cancer patients with brain metastasis compared with an unselected control population, and to assess the outcome of brain metastasis patients with triple-negative breast cancers (TNBC) compared with the other subgroups. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2860909 Mon, 05 Oct 2009 17:38:46 +0100 2860909 http://www.medworm.com/index.php?rid=2860908&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001903%2Fabstract%3Frss%3Dyes The paper by Pemberton et al. is an interesting non-randomised comparison of continuous hyperfractionated accelerated radiotherapy (CHART) and 55Gy in 20 fractions. The original CHART trial showed superiority for CHART, but we were never certain whether this was a reflection of the low dose (60Gy in 30 fractions) in the standard arm. The evidence for 60Gy in 30 fractions being the gold standard was tenuous . (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2860908 Mon, 05 Oct 2009 17:38:46 +0100 2860908 http://www.medworm.com/index.php?rid=2860907&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002623%2Fabstract%3Frss%3Dyes Conclusion: Reducing the action level at which the systematic error is corrected improves the probability of treatment delivery accuracy. Using the NAL correction protocol reduces the number of fractions that have set-up displacements outside a 5mm CTV–PTV margin. Although a 5mm margin is probably sufficient for standard HNC radiotherapy, change to a 3mm margin is not favoured at our centre without access to daily image-guided radiotherapy. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2860907 Mon, 05 Oct 2009 17:38:46 +0100 2860907 http://www.medworm.com/index.php?rid=2860906&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002362%2Fabstract%3Frss%3Dyes Conclusions: The present study shows a simple way of incorporating organ motion into the planning process and can be adopted by any centre without major strain on healthcare resources. The use of individualised margins reduced PTV volume and the dose to OARs. This may offer an opportunity for dose escalation to try and further improve local control. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2860906 Mon, 05 Oct 2009 17:38:46 +0100 2860906 http://www.medworm.com/index.php?rid=2860905&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002295%2Fabstract%3Frss%3Dyes Abstract: Aims: To evaluate the integral dose to organs at risk (OARs), normal tissue and the whole body in three-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT) and helical tomotherapy for whole pelvic radiotherapy (WPRT) in postoperative endometrial cancer patients.Materials and methods: We selected 10 patients with endometrial cancer undergoing postoperative WPRT. Plans of 6MV-3DCRT, 18MV-3DCRT, 6MV-IMRT, 18MV-IMRT and helical tomotherapy were developed for each patient. The integral doses to OARs, normal tissue and the whole body were compared.Results: Compared with 3DCRT, both IMRT and helical tomotherapy significantly improved dose conformity and the integral doses to OARs (8.8–29.9%, P (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2860905 Mon, 05 Oct 2009 17:38:46 +0100 2860905 http://www.medworm.com/index.php?rid=2860904&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002374%2Fabstract%3Frss%3Dyes Abstract: Sarcomas are a rare, complex group of childhood and adult neoplasms with differentiation towards mesenchymal tissue, which may arise almost anywhere in the body. Although pathologically diverse, they frequently exhibit similar clinical presentations and radiological features. Correct histopathological diagnosis is therefore crucial, but there is overlap between histological patterns of malignant tumours, between benign and malignant lesions, and with non-mesenchymal tumours. Immunohistochemistry and molecular genetic techniques, the latter to detect tumour-specific alterations, add significantly to histological interpretation, but several groups of tumours still lack reliable immunohistochemical markers or reproducible genetic changes. The classification of sarcomas is incomplete... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2860904 Mon, 05 Oct 2009 17:38:46 +0100 2860904 http://www.medworm.com/index.php?rid=2860903&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665550900154X%2Fabstract%3Frss%3Dyes Conclusions: These data suggest that the administered dose after EBRT for prostate cancer to the colon, excluding the rectum, may be below the Gy unit in sCRC patients. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2860903 Mon, 05 Oct 2009 17:38:46 +0100 2860903 http://www.medworm.com/index.php?rid=2860902&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002647%2Fabstract%3Frss%3Dyes Conclusion: SIB IMRT as used in this study was feasible, although associated with increased rates of mucosal and dermal toxicity. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2860902 Mon, 05 Oct 2009 17:38:46 +0100 2860902 http://www.medworm.com/index.php?rid=2860901&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002386%2Fabstract%3Frss%3Dyes Conclusion: Favourable long-term results of APBI in terms of superior body image perception and lesser financial difficulties compared with WBRT need to be confirmed in larger prospective studies investigating the effect of APBI on quality of life and health economics in different ethnic groups and health care set-ups. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2860901 Mon, 05 Oct 2009 17:38:45 +0100 2860901 http://www.medworm.com/index.php?rid=2860900&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002301%2Fabstract%3Frss%3Dyes Bisphosphonates, external beam radiotherapy and bone-seeking radiopharmaceuticals (BSRs) have an established role for the management of metastatic bone disease. Radiotherapy achieves significant pain relief and a decrease in local skeletal complication rates . The exact mechanism by which pain relief is achieved is unknown. It has been suggested that a high level of tumour and inflammatory cell kill and the subsequent decrease in osteoclastic activity play a role . BSRs bring about a similar effect in areas of increased uptake by local radiation emission. These mechanisms may be an important link for the possible synergistic activity with bisphosphonates. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2860900 Mon, 05 Oct 2009 17:38:45 +0100 2860900 http://www.medworm.com/index.php?rid=2860899&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002325%2Fabstract%3Frss%3Dyes Conventional radiotherapy is an integral part of treatment for bone metastasis as primary treatment for symptomatic sites or as an adjuvant treatment after surgical decompression of spinal cord compression or therapeutic or prophylactic internal fixation of the involved bone . (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2860899 Mon, 05 Oct 2009 17:38:45 +0100 2860899 http://www.medworm.com/index.php?rid=2860898&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002349%2Fabstract%3Frss%3Dyes A disproportionate percentage of healthcare funds are spent on patients in the final days of life . The aging of the populations of several countries will require the distribution of healthcare resources over a greater number of patients, necessitating cost vs. benefit analyses of end of life interventions. The comparison of treatment outcomes requires the evaluation of both objective and subjective measures, as well as their effects on quality of life. The value of the results from prospective trials may therefore only be maximised by homogeneity of data collection and the reporting of results. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2860898 Mon, 05 Oct 2009 17:38:45 +0100 2860898 http://www.medworm.com/index.php?rid=2860897&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002313%2Fabstract%3Frss%3Dyes Abstract: Although it may be argued that single fraction (SF) radiotherapy (RT) should be regarded as the standard palliative treatment for pain due to uncomplicated bone metastases, its widespread clinical use is still underexploited. In this chapter, the authors discuss a number of surveys investigating doctors and patients' preferences for palliative RT schedules, discuss the possible reasons for this phenomenon, and suggest potential strategies to increase the use of SF. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2860897 Mon, 05 Oct 2009 17:38:45 +0100 2860897 http://www.medworm.com/index.php?rid=2860896&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002350%2Fabstract%3Frss%3Dyes Although the majority of patients with newly diagnosed cancer will be cured, a substantial number will develop metastatic disease. In most of these patients, treatment is palliative in intent. The goal of palliative treatment is to return the patient to an optimum quality of life as soon as possible, recognizing that protracted treatments may occupy much of the patients' remaining life . For painful bone metastases, the ideal treatment would be clinically effective, minimally toxic, time efficient and cost conscious. Multiple randomised trials have shown that there is such a treatment: single fraction palliative radiotherapy . Why is this treatment underutilised in the United States – and indeed in the rest of the world ? (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2860896 Mon, 05 Oct 2009 17:38:45 +0100 2860896 http://www.medworm.com/index.php?rid=2860895&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002337%2Fabstract%3Frss%3Dyes External beam radiotherapy continues to be a mainstay for the successful treatment of patients with symptoms caused by cancer. The delivery of palliative radiotherapy is effective, time-efficient, relatively inexpensive and associated with a low risk of side-effects . However, the management of patients with painful bone metastases is complex and requires the integration of several medical disciplines. That complexity, coupled with the lack of palliative care guidelines, helped lead to the formation of the First International Consensus Workshop on radiation in the treatment of metastatic and locally advanced cancer in 1990 . A group of 116 experts met and generated consensus statements for the treatment of bone metastasis, brain metastasis and locally advanced lung cancer. The group review... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2860895 Mon, 05 Oct 2009 17:38:45 +0100 2860895 http://www.medworm.com/index.php?rid=2771426&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001587%2Fabstract%3Frss%3Dyes 24 April 2009 (Royal College of Physicians, London) (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2771426 Mon, 07 Sep 2009 17:12:11 +0100 2771426 http://www.medworm.com/index.php?rid=2771425&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001563%2Fabstract%3Frss%3Dyes Sir — I am interested to read the letter and proposal by Guglani and Benstead and would be very much in favour of taking forward its incorporation into the curriculum. There are many examples of communication skills components to higher medical training curricula, some of which incorporate ethical and legal issues. Closely related to oncology is palliative medicine, in which communication skills to be obtained are outlined as a subheading under psychosocial care, and ethical issues to be understood and practiced are listed in their own paragraph later . There are also many different formats of medical curricula, not all of which yet seem to fully embrace the educationalists' view of learning outcomes. The Postgraduate Medical Education and Training Board has set out the requirement to e... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2771425 Mon, 07 Sep 2009 17:12:11 +0100 2771425 http://www.medworm.com/index.php?rid=2771424&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001484%2Fabstract%3Frss%3Dyes A 67-year-old woman had a left mastectomy for breast carcinoma in 1996. Ten years later she developed chest wall recurrence, which was excised and treated with postoperative radiotherapy without complications. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2771424 Mon, 07 Sep 2009 17:12:11 +0100 2771424 http://www.medworm.com/index.php?rid=2771423&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001393%2Fabstract%3Frss%3Dyes Sir — After several reports of an increased rate of central nervous system (CNS) relapse in patients with metastatic HER-2-positive breast tumours treated with trastuzumab , we retrospectively examined a series of breast cancer patients with brain metastases for the presence of HER-2 and oestrogen receptors. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2771423 Mon, 07 Sep 2009 17:12:11 +0100 2771423 http://www.medworm.com/index.php?rid=2771422&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665550900106X%2Fabstract%3Frss%3Dyes Sir — We would like to report the first case to our knowledge of radiation recall dermatitis (RRD) triggered by trastuzumab (Herceptin®). A 71-year-old woman with previous left mastectomy for ductal carcinoma in situ presented with distortion of her right breast in February 2008. Ultrasound-guided core biopsy confirmed invasive ductal carcinoma. She underwent right-sided mastectomy and axillary nodal dissection. Histopathology confirmed multifocal invasive breast cancer. Two tumours were identified: a grade III, 35mm, oestrogen receptor-positive, progesterone receptor-negative, Her2-positive invasive ductal cancer and a grade II, 35mm, oestrogen receptor-positive, progesterone receptor-positive, Her2-negative, invasive lobular cancer. The ductal carcinoma was Her-2 (Herceptest) 2+ and f... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2771422 Mon, 07 Sep 2009 17:12:11 +0100 2771422 http://www.medworm.com/index.php?rid=2771421&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001046%2Fabstract%3Frss%3Dyes A 62-year-old man underwent a right nephrectomy for clear cell carcinoma of the kidney, but relapsed within 1 year with liver metastases. He was initially treated with sorafenib 400mg orally twice a day; a baseline scan revealed a 32mm index liver metastasis (A). Repeated scanning 6 months later showed progression of the liver metastasis increasing to 54mm (B). Sunitinib, 50mg orally once a day, using a regimen of 4 weeks on and 2 weeks off treatment, was substituted. Three months later, repeat scanning showed a response (C), with a reduction in the liver metastasis to 41mm, which is maintained out to 1 year. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2771421 Mon, 07 Sep 2009 17:12:11 +0100 2771421 http://www.medworm.com/index.php?rid=2771420&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000697%2Fabstract%3Frss%3Dyes We report an unusual case of skin hyperpigmentation and radiation recall phenomenon after the administration of capecitabine. A 44-year-old patient with a previous history of right mastectomy for an invasive ductal carcinoma underwent neoadjuvant chemotherapy (six cycles of adriamycin and cyclophosphamide), left mastectomy, chest wall and supraclavicular fossa radiotherapy for a T3, oestrogen receptor-positive second primary invasive lobular carcinoma in the left breast. She developed pleural, liver and bone metastasis while still on adjuvant anastrazole about 28 months from the completion of her left chest wall radiotherapy in October 2002. On relapse she was treated with several lines of palliative chemotherapy, including vinorelbine, paclitaxel and hormonal therapy with letrozole and f... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2771420 Mon, 07 Sep 2009 17:12:10 +0100 2771420 http://www.medworm.com/index.php?rid=2771419&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001885%2Fabstract%3Frss%3Dyes Conclusions: In this small cohort of patients with stage I peripheral NSCLC, robotic stereotactic radiotherapy seems to be a safe and obviously superior alternative to conventionally fractionated radiotherapy, with results that may be approaching those obtained with lobectomy without the associated morbidity. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2771419 Mon, 07 Sep 2009 17:12:10 +0100 2771419 http://www.medworm.com/index.php?rid=2771418&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001976%2Fabstract%3Frss%3Dyes Conclusions: The outcome of the present series was excellent, and matched well with other publications. A high systemic failure remains a major obstacle to cure young NPC patients. More efforts should be made to improve both survival and quality of life. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2771418 Mon, 07 Sep 2009 17:12:10 +0100 2771418 http://www.medworm.com/index.php?rid=2771417&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001897%2Fabstract%3Frss%3Dyes Conclusions: Compared with patients receiving treatment, patients denied access to sunitinib and sorafenib had substantially worse survival outcomes, despite receiving treatment from the same clinical team. Access to the new drugs did not have an effect on overall use of National Health Service resources by funded patients. Modern treatments for advanced renal cancer should be available to all National Health Service patients with the disease. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2771417 Mon, 07 Sep 2009 17:12:10 +0100 2771417 http://www.medworm.com/index.php?rid=2771416&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001447%2Fabstract%3Frss%3Dyes Conclusions: The severity of acute bowel toxicity is related to pelvic irradiation and dose intensity. The severity of acute bladder toxicity depends on T-stage. The increase in dose intensity is associated with shorter latency to maximum acute bladder and bowel toxicity. The severity of acute bladder and bowel toxicity influences the risk of late effects from those organs. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2771416 Mon, 07 Sep 2009 17:12:10 +0100 2771416 http://www.medworm.com/index.php?rid=2771415&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001423%2Fabstract%3Frss%3Dyes Conclusions: GBM occurs at an increased frequency and younger age in the HIV population than in the general population. HIV itself is not found in glioma specimens, but the effect of HIV infection on reduced immune surveillance is thought to promote the development of these tumours. The approach to management of HIV-positive patients with GBM should be the same as the general population, using surgery, radiotherapy and chemotherapy. Vincristine should be used with caution due to potential interactions with highly active antiretroviral therapy, causing an increased rate of autonomic neuropathy. Continuous low-dose temozolomide treatment should also be used cautiously because of potential additive lymphopenia. Survival of glioma patients with HIV is dictated by their tumour, not their HIV st... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2771415 Mon, 07 Sep 2009 17:12:10 +0100 2771415 http://www.medworm.com/index.php?rid=2771414&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001964%2Fabstract%3Frss%3Dyes Conclusions: This audit confirms the underprovision of radiotherapy in England and shows that it is largely accounted for by low access rates of 37% rather than the 50% accepted in the literature. In consequence we estimate that 33 881 patients (13.9%) of the 243 748 patients diagnosed with cancer in England during 2006/2007 did not receive the radiotherapy we would have expected. Some of this gap in provision may be accounted for by differences in stage and performance status, which limit treatment options, for example in lung cancer. The NRAG model should be updated to take account of new data from this and other national audits, to ensure that it describes the stage and performance status of English patients and is sensitive to the range of professional opinion about treatment optio... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2771414 Mon, 07 Sep 2009 17:12:09 +0100 2771414 http://www.medworm.com/index.php?rid=2771413&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509002222%2Fabstract%3Frss%3Dyes With an aging population, the incidence of cancer is forecast to increase by around one-third by 2020 , resulting in a progressive increase in the workload and resource requirements for cancer care services in the coming years. Although the medical workforce in oncology has expanded considerably since 2000 , good planning is required to provide a skilled and flexible workforce for the future to deliver the care that our patients require and deserve . (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2771413 Mon, 07 Sep 2009 17:12:09 +0100 2771413 http://www.medworm.com/index.php?rid=2680555&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001873%2Fabstract%3Frss%3Dyes Abstract: In the radical treatment of cervical cancer there is now overwhelming evidence to support cisplatin-based chemoradiation with radical radiotherapy for locally advanced disease. This is, however, at the expense of increased acute toxicity, in particular grade 3 and 4 haematological toxicity and acute gastrointestinal toxicity. In the setting of the developing world it is important to note that the impact of chemoradiation over radiotherapy alone diminishes with advancing stage and the overall benefit where the patients have predominantly stage III and IV disease is small and particularly where supportive therapy is limited may be outweighed by increased toxicity. Greater gains may be achieved by attention to delivering high-quality conventional radiotherapy, including brachytherap... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2680555 Sat, 08 Aug 2009 11:35:56 +0100 2680555 http://www.medworm.com/index.php?rid=2680554&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001502%2Fabstract%3Frss%3Dyes Abstract: Standard treatment for muscle-invasive bladder cancer is cystectomy. Multimodality treatment, including transurethral resection of the bladder tumour, radiation therapy, chemotherapy and deep regional hyperthermia, has been shown to produce survival rates comparable with those of cystectomy. With these programmes, cystectomy has been reserved for patients with incomplete response or local relapse. During the past two decades, organ preservation by multimodality treatment has been investigated in prospective series from single centres and co-operative groups, with more than 1000 patients included. Five-year overall survival rates in the range of 50–60% have been reported, and about three-quarters of the surviving patients maintained their bladder. Clinical criteria helpful in de... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2680554 Sat, 08 Aug 2009 11:35:55 +0100 2680554 http://www.medworm.com/index.php?rid=2680553&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001526%2Fabstract%3Frss%3Dyes Abstract: Over the past 30 years, significant advances have been made in the integration of radiation therapy and chemotherapy in the treatment of patients with localised gastrointestinal malignancies. The therapeutic goal of chemoradiotherapy is to enhance local control resulting in improved survival and outcome of these patients. To define the optimal sequence, agents and efficacy of these modalities, an array of randomised studies have been conducted in malignancies of the oesophagus, stomach, pancreas, colon, rectum and anus. In oesophageal cancer, recent studies from Germany and France indicate that patients treated with ‘definitive’ chemoradiotherapy have similar survival to patients undergoing neoadjuvant chemoradiotherapy followed by surgery. For patients with locally advanced ... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2680553 Sat, 08 Aug 2009 11:35:55 +0100 2680553 http://www.medworm.com/index.php?rid=2680552&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001113%2Fabstract%3Frss%3Dyes Abstract: Radiochemotherapy has become a standard approach in locally advanced non-small cell lung cancer and limited disease small cell lung cancer. Most of the data supporting this observation come from the developed world and only extremely rarely have good-quality clinical trials been carried out in developing countries. It is therefore of paramount importance to put the experience of the developed world into the context of the limited resources and other health care problems of developing countries. In this overview, the problems with the implementation of such data are discussed. The necessity of carrying out clinical trials specifically designed to address the needs of developing countries is emphasised. The research on cheaper ways of radiochemotherapy combination should be encoura... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2680552 Sat, 08 Aug 2009 11:35:55 +0100 2680552 http://www.medworm.com/index.php?rid=2680551&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001411%2Fabstract%3Frss%3Dyes Abstract: Radiotherapy and chemotherapy have established roles in the multidisciplinary management of early breast cancer. The optimal integration of these treatment modalities is controversial. The most common approach is to deliver each treatment modality sequentially. For patients with close surgical margins or with other risk factors for local recurrences, initiation of adjuvant treatment with radiotherapy is recommended. A sandwich regimen is not the preferred schedule because of a decreased dose density for anthracyline- and taxane-based regimens. However, it can be an option for patients receiving adjuvant cyclophosphamide, methotrexate and fluorouracil (CMF). Concomitant radio- and chemotherapy remain in principle an attractive treatment schedule to provide an additive interaction ... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2680551 Sat, 08 Aug 2009 11:35:55 +0100 2680551 http://www.medworm.com/index.php?rid=2680550&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001538%2Fabstract%3Frss%3Dyes Abstract: Squamous cell carcinoma of the head and neck (SCCHN) is a common disease that develops in the upper aerodigestive epithelium. The most important risk factors are tobacco and alcohol consumption. There is also increasing evidence that human papillomavirus plays an important role in the cause of SCCHN. The complex anatomy, the vital functions of the upper aerodigestive tract and the close proximity to vital structures, explain that the goal of treatment is not only to improve survival outcomes, but also to preserve organ function. Radiotherapy and surgery are the standard modalities of treatment, reflecting the locoregional predominance of SCCHN. Chemotherapy plays an important role in the treatment of patients with locoregionally advanced disease, in conjunction with radiotherapy ... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2680550 Sat, 08 Aug 2009 11:35:55 +0100 2680550 http://www.medworm.com/index.php?rid=2680549&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001496%2Fabstract%3Frss%3Dyes Abstract: In order to examine the current standards of care regarding combined radio- and chemotherapy for adult patients with brain tumours, a review was carried out of recent studies examining surgery, radiotherapy and chemotherapy in high-grade glioma, medulloblastoma and primary central nervous system lymphoma. The integration of the oral cytotoxic agent temozolomide into current treatment protocols of postoperative combination therapy with radiation and drugs in high-grade glioma is discussed. In glioblastoma, the landmark phase III trial by the European Organisation for Research and Treatment of Cancer and the National Cancer Institute of Canada has defined the current standard of care. Attempts to optimise the schedule of temozolomide administration and to combine this regimen with ... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2680549 Sat, 08 Aug 2009 11:35:55 +0100 2680549 http://www.medworm.com/index.php?rid=2680548&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001575%2Fabstract%3Frss%3Dyes Cancer is one of the major health problems worldwide. In 2010 it will become the leading cause of death worldwide. Although the developed world enjoys the benefits of active prevention, early detection and effective treatments, some 6 million people still die of cancer every year. It is estimated that more patients die of cancer than of the major infections, malaria, tuberculosis and HIV, combined. This can be attributed to an interplay between several factors. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2680548 Sat, 08 Aug 2009 11:35:55 +0100 2680548 http://www.medworm.com/index.php?rid=2586805&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001472%2Fabstract%3Frss%3Dyes Abstract: The United Kingdom Radiation Oncology (UKRO) conference was formed as a result of discussions held in the early 1990s and the first meeting was held in York in 2001. Cardiff, Wales, was the setting of the fifth UKRO conference during April 2009. These meetings have allowed all the sub-disciplines of radiation oncology to meet over 3 days in order to provide education on most technical aspects of modern radiotherapy, with key invited speakers from abroad. The UK and other countries face considerable dilemmas as to how best to implement new treatment techniques, including particle therapy, in a state-funded health service. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2586805 Fri, 10 Jul 2009 11:37:53 +0100 2586805 http://www.medworm.com/index.php?rid=2586804&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001071%2Fabstract%3Frss%3Dyes We report our outcome data for 33 Gorlin patients (138 lesions) treated with PDT. Lesion thicknesses were assessed using ultrasound, both prior to treatment and during follow-up, to quantify treatment response and to guide the choice of treatment methods. Topical PDT was used to treat superficial lesions (2 mm).Results and conclusions: Local control rates of 56.3% at 12 months were achieved overall. The use of a systemic photosensitiser +/− interstitial light delivery extended the remit of PDT, allowing thicker lesions (>2 mm) to be treated, resulting in local control rates of 59.3% in this group. PDT can be considered as a treatment option for patients with multiple BCCs as a result of Gorlin syndrome. The use of ultrasound to accurately assess lesion thickness helps to select the optim... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2586804 Fri, 10 Jul 2009 11:37:53 +0100 2586804 http://www.medworm.com/index.php?rid=2586803&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000703%2Fabstract%3Frss%3Dyes Conclusions: Radiotherapy to a total dose of 50Gy in 16 fractions for T1N0M0 squamous cell carcinoma of the larynx offers high locoregional control rates with voice preservation. These results from a hypofractionated radiotherapy schedule are comparable with other longer fractionation schedules and offer potential for optimising resource usage. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2586803 Fri, 10 Jul 2009 11:37:53 +0100 2586803 http://www.medworm.com/index.php?rid=2586802&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001058%2Fabstract%3Frss%3Dyes Conclusion: In this phase I trial of concurrent radiation and combination chemotherapy with weekly paclitaxel and cisplatin (30mg/m2/week), the MTD of paclitaxel was found to be 40mg/m2. This combination was feasible, with an acceptable toxicity profile. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2586802 Fri, 10 Jul 2009 11:37:53 +0100 2586802 http://www.medworm.com/index.php?rid=2586801&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001101%2Fabstract%3Frss%3Dyes Conclusions: Our study has shown that a single-plan procedure achieved acceptable dosimetry in most patients. However, the individualised plan improved dosimetry by accounting for variations in applicator geometry and the position of critical organs. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2586801 Fri, 10 Jul 2009 11:37:53 +0100 2586801 http://www.medworm.com/index.php?rid=2586800&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000338%2Fabstract%3Frss%3Dyes Abstract: Aims: An observational cohort study in patients undergoing treatment at a single cancer centre to evaluate the usefulness of providing written information on exercise and fatigue to patients at the start of their treatment, to assess whether patients exercised during treatment and their level of fatigue before and after treatment.Materials and methods: Participants were 205 patients of mean age 63.4 years (115 men and 90 women), starting a course of radical radiotherapy, postoperative radiotherapy and palliative radiotherapy or chemotherapy between October 2004 and June 2005 for genitourinary, gynaecological or breast cancer. A patient-held folder was provided, containing written information on cancer or treatment-related fatigue and the use of exercise to manage this, together w... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2586800 Fri, 10 Jul 2009 11:37:53 +0100 2586800 http://www.medworm.com/index.php?rid=2586799&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001435%2Fabstract%3Frss%3Dyes Conclusion: There was no evidence that talabostat enhanced the clinical activity of docetaxel in patients with NSCLC. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2586799 Fri, 10 Jul 2009 11:37:53 +0100 2586799 http://www.medworm.com/index.php?rid=2586798&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001125%2Fabstract%3Frss%3Dyes Abstract: Malignant diseases of the lungs and pleura are common causes of morbidity and mortality throughout the developed world. Determining the appropriate treatment strategies for an individual patient requires a multidisciplinary approach integrating input from many disciplines including pathology. In this overview, we discuss diagnosis of lung and pleural malignancy from the pathologist’s perspective, placing particular emphasis on methods available to obtain material for pathological assessment, and their implications for diagnosis and provision of information to guide patient management. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2586798 Fri, 10 Jul 2009 11:37:53 +0100 2586798 http://www.medworm.com/index.php?rid=2586797&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000314%2Fabstract%3Frss%3Dyes Abstract: Although BRCA1-associated breast carcinomas are frequently detected in nodal-negative stage, they typically present with an aggressive histopathological phenotype that is reflected by a poor prognosis and an increased risk for distant metastatic spread. Recent in vitro data suggest a high sensitivity of BRCA1-associated carcinomas to platinum-based chemotherapy and a lower sensitivity to anthracyclines and taxanes. This is explained by the key role of BRCA1 in DNA double-strand repair via homologous recombination, thereby leading to a higher sensitivity to DNA intercalating agents, such as platinum. Here we present the case of a woman suffering from BRCA1-associated metastatic breast carcinoma that was resistant to docetaxel, but responded strongly to cisplatin-containing chemoth... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2586797 Fri, 10 Jul 2009 11:37:53 +0100 2586797 http://www.medworm.com/index.php?rid=2586796&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665550900140X%2Fabstract%3Frss%3Dyes We present a case of dramatic response of poor prognosis cancer in a lady with a germline mutation in the BRCA2 gene who was exposed to platinum containing chemotherapy. She is cancer-free 10 years’ later. Such cases provide clinical scenarios for the basis of trials of platinum-like agents in individuals with BRCA mutations who develop cancer. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2586796 Fri, 10 Jul 2009 11:37:53 +0100 2586796 http://www.medworm.com/index.php?rid=2586795&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001551%2Fabstract%3Frss%3Dyes The aim of cancer treatment is to give the most effective treatment to the right people, in other words, to ‘tailor’ cancer treatment for an individual patient as closely as possible. Tailoring of cancer therapy is an established concept and is attempted daily when we use a tumour type, stage and phenotype, as well as consider the host factors of age, gender, performance status and co-morbidities to direct selection of appropriate therapy. However, the absolute improvements in survival are in the order of 5–10% with most adjuvant systemic treatments. Further inroads into cancer morbidity and mortality require more targeted approaches to treatment and effective treatment selection for individual patients. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2586795 Fri, 10 Jul 2009 11:37:53 +0100 2586795 http://www.medworm.com/index.php?rid=2586794&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001514%2Fabstract%3Frss%3Dyes Conclusions: There are substantial differences across the UK in the radiotherapy provided to patients and its timeliness. Radiotherapy capacity does not reflect regional variations in cancer incidence across the UK (3618–5800 cases per million per year). In addition, deprivation is a major unrecognised influence on radiotherapy access rates. In regions with higher levels of deprivation, fewer patients with cancer receive radiotherapy and the proportion treated radically is lower. This probably reflects late presentation with advanced disease, poor performance status and co-morbid illness. To provide an equitable, evidence-based service, the needs of the local population should be assessed using demand modelling based on local cancer incidence. Ideally this should include data on deprivat... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2586794 Fri, 10 Jul 2009 11:37:52 +0100 2586794 http://www.medworm.com/index.php?rid=2410344&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665550900048X%2Fabstract%3Frss%3Dyes In the above manuscript b should have appeared as below. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2410344 Fri, 15 May 2009 19:44:54 +0100 2410344 http://www.medworm.com/index.php?rid=2410343&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000491%2Fabstract%3Frss%3Dyes Sir — Augured by advances in science and technology, medicine has undergone a revolution in the last century. The present day clinicians now talk in terms of ‘translational medicine’, phased trials and, finally, randomised controlled trials (RCT). Wikipedia defines a randomised trial thus: ‘A randomized controlled trial (RCT) is a type of scientific experiment most commonly used in testing the efficacy or effectiveness of healthcare services (such as medicine or nursing) or health technologies (such as pharmaceuticals, medical devices or surgery)’. RCTs have been hailed by purists for providing what is known as ‘level I evidence’ . Indeed, the number of hits in the Pubmed for the term ‘randomised controlled trial’ for each year shows a continuous sustained growth from 200... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2410343 Fri, 15 May 2009 19:44:52 +0100 2410343 http://www.medworm.com/index.php?rid=2410342&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000442%2Fabstract%3Frss%3Dyes Sir — In the UK and Australia, a number of health campaigns have been conducted to improve knowledge of risk factors for cancer, with the aim of promoting earlier consultation and modifying lifestyle choices. For example, the health campaign for skin cancer in Australia has been established since 1980; the ‘Slip! Slap! Slop!’ and ‘Sun Smart’ campaigns were designed to increase awareness about sun exposure . By contrast, the UK Government has only set up a prevention campaign for skin cancer relatively recently, due to the rising incidence rates for malignant melanoma . (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2410342 Fri, 15 May 2009 19:44:51 +0100 2410342 http://www.medworm.com/index.php?rid=2410341&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000405%2Fabstract%3Frss%3Dyes Sir — We read with interest the article by Barraclough et al. regarding appropriate estimation of renal function based on glomerular filtration rate (GFR) in cancer patients. Accurate determination of GFR is crucial to ensure minimal nephrotoxicity in these patients when treating with chemotherapeutic drugs. Indeed, the abbreviated Modification of Diet in Renal Disease (MDRD) and the Cockcroft–Gault equations for estimating GFR using serum creatinine levels have not been validated in certain groups, such as oncology patients . We therefore report preliminary results on our ongoing study assessing renal function in 57 adult oncology patients using cystatin C levels and equations to calculate GFR. We compared estimated GFR by the MDRD and Cockcroft–Gault formulae from plasma creatinin... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2410341 Fri, 15 May 2009 19:44:48 +0100 2410341 http://www.medworm.com/index.php?rid=2410340&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000272%2Fabstract%3Frss%3Dyes Sir — We read with great interest the report by Mitchell et al. on the early efficacy and tolerability of I125 permanent prostate brachytherapy from a UK multi-institutional database. Our institution (University Hospital Birmingham) has been using I125 therapy as a radical treatment option for localised prostate cancer since January 2006. Although treatment was initially only carried out by one consultant in the early stages while logistical issues were being addressed, there are now others trained and carrying out the technique. Our expertise is now hopefully beginning to match those from other centres. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2410340 Fri, 15 May 2009 19:44:46 +0100 2410340 http://www.medworm.com/index.php?rid=2410339&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000685%2Fabstract%3Frss%3Dyes Conclusions: These findings confirm the increased incidence and improved outcome of cancer in teenagers and young adults. Future analyses should investigate trends in bone tumour survival across regions, survival by socioeconomic status and the influence of specialised care on further improvements in survival. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2410339 Fri, 15 May 2009 19:44:42 +0100 2410339 http://www.medworm.com/index.php?rid=2410338&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000429%2Fabstract%3Frss%3Dyes Abstract: Aims: To compare the dosimetric outcome of various conventional stereotactic radiotherapy (SRT) techniques with intensity-modulated stereotactic radiotherapy (IMSRT) in brain tumours of varying shape, size, location and proximity to organs at risk (OARs).Materials and methods: Fused computed tomography and magnetic resonance imaging datasets of four patients with different brain tumours previously treated with non-coplanar static conformal fields (SCF) were re-planned on the BrainScan treatment planning system using non-coplanar conformal arcs (CA), dynamic conformal arcs (DCA) and IMSRT with coplanar (IMSRT_CP) or non-coplanar (IMSRT_NCP) beam arrangement. Beam shaping and intensity modulation were carried out using a BrainLab micromultileaf collimator. The primary objective for... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2410338 Fri, 15 May 2009 19:44:41 +0100 2410338 http://www.medworm.com/index.php?rid=2410337&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000454%2Fabstract%3Frss%3Dyes Conclusions: VMAT is able to boost more of the CTV to ≥120% than cIMRT without contravening OAR dose constraints, and uses 48% fewer monitor units. Treatment times were 61% less than with cIMRT. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2410337 Fri, 15 May 2009 19:44:38 +0100 2410337 http://www.medworm.com/index.php?rid=2410336&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000399%2Fabstract%3Frss%3Dyes Conclusions: Continuous infusional 5-fluorouracil has activity in transitional cell carcinoma of the urinary tract. Prolonged fluoropyrimidine administration may be a useful component of future combination regimens for this disease, particularly in patients with poor renal function. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2410336 Fri, 15 May 2009 19:44:37 +0100 2410336 http://www.medworm.com/index.php?rid=2410335&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000478%2Fabstract%3Frss%3Dyes Abstract: Aims: Organ motion is the principle source of error in bladder cancer radiotherapy. The aim of this study was to evaluate ultrasound bladder volume measurement as a surrogate measure of organ motion during radiotherapy: (1) to assess inter- and intra-fraction bladder variation and (2) as a potential treatment verification tool.Materials and methods: Twenty patients receiving radical radiotherapy for bladder cancer underwent post-void ultrasound bladder volume measurement at the time of radiotherapy treatment planning (RTP), and immediately before (post-void) and after receiving daily fractions.Results: Ultrasound bladder volume measurement was found to be a simple and acceptable method to estimate relative bladder volume changes. Six patients showed significant changes to post-vo... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2410335 Fri, 15 May 2009 19:44:34 +0100 2410335 http://www.medworm.com/index.php?rid=2410334&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001083%2Fabstract%3Frss%3Dyes Despite data to support the use of radiotherapy as a radical treatment option for muscle invasive bladder cancer, its role has not been universally adopted. Historical series, which are subject to case selection bias, issues of stage migration (Will Rogers effect) and the use of outdated radiotherapy techniques, report inferior outcomes for radiotherapy compared with cystectomy . More recent series, however, report similar outcomes . There has never been a randomised comparison (although this is now ongoing in the National Cancer Research Institute "SPARE" trial). (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2410334 Fri, 15 May 2009 19:44:33 +0100 2410334 http://www.medworm.com/index.php?rid=2410333&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000466%2Fabstract%3Frss%3Dyes Conclusions: This single-centre retrospective study supports the treatment for selected cases of anal canal cancer with smaller than standard radiation fields, avoiding prophylactic inguinal nodal irradiation. Hopefully this will translate into reduced acute and late toxicity. In future studies we would suggest that consideration is given as to whether omission of prophylactic inguinal nodal irradiation for early stage tumours should be explored. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2410333 Fri, 15 May 2009 19:44:30 +0100 2410333 http://www.medworm.com/index.php?rid=2410332&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000508%2Fabstract%3Frss%3Dyes Conclusion: After curative radiotherapy, all patients presented some radiographic abnormality. There was no correlation with lung symptoms. The assessment of radiation-induced lung toxicity differs depending on the scoring system used. Comparison of reports that use different scoring scales should be made with caution. A scale based on symptoms only, such as the NCI-CTC scale, may be more appropriate to evaluate long-term toxicity after curative radiotherapy for lung cancer. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2410332 Fri, 15 May 2009 19:44:27 +0100 2410332 http://www.medworm.com/index.php?rid=2410331&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001137%2Fabstract%3Frss%3Dyes We are disappointed that Professor Coleman is unhappy with our guideline, particularly as we believe it largely reflects current practice in the management of advanced breast cancer in many units in the UK and beyond. Our recommendations describe the minimum that should be provided for the management of lymphoedema, which will result in improved lymphoedema services in some areas, and, on the basis of good evidence, we have recommended exercise programmes for patients with cancer-related fatigue. But little else is really new. We knew that a recommendation about stopping trastuzumab on disease progression outside the central nervous system would be controversial, but we are confident the right recommendation has been made, as discussed below. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2410331 Fri, 15 May 2009 19:44:26 +0100 2410331 http://www.medworm.com/index.php?rid=2410330&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509001095%2Fabstract%3Frss%3Dyes Evidence-based medicine has dramatically improved clinical standards, and oncology is blessed with perhaps more evidence than any other medical discipline on which to formulate sensible management guidelines. It is thus a great shame that the National Institute for Health and Clinical Excellence (NICE) in their guidelines on the management of advanced breast cancer have missed the opportunity to provide guidelines that will improve the management of nearly 11 000 women who die of this disease every year. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2410330 Fri, 15 May 2009 19:44:25 +0100 2410330 http://www.medworm.com/index.php?rid=2344888&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655508004913%2Fabstract%3Frss%3Dyes This study established whether monocyte-derived dendritic cells injected into primary tumours were capable of overcoming this environment and migrating to local lymph nodes. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2344888 Mon, 20 Apr 2009 18:40:42 +0100 2344888 http://www.medworm.com/index.php?rid=2344887&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000259%2Fabstract%3Frss%3Dyes In this study, we investigated the association between TrkB expression level and chemo/radiotherapy resistance in oesophageal squamous cell carcinoma (ESCC) tissue and cell lines. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2344887 Mon, 20 Apr 2009 18:40:42 +0100 2344887 http://www.medworm.com/index.php?rid=2344886&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000247%2Fabstract%3Frss%3Dyes Sir — A 66-year-old woman presented to our unit with cardiac-sounding chest pain. Three months previously she had had a total right mastectomy for carcinoma of the breast (T3G2N1) and during the last 12 days had undergone radiotherapy, receiving a cumulative dose of 21.36Gy from medial, lateral and supraclavicular fields. Her only other past history was of treated hypertension. She was a non-smoker with a low-risk lipid profile and no family history of ischaemic heart disease. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2344886 Mon, 20 Apr 2009 18:40:39 +0100 2344886 http://www.medworm.com/index.php?rid=2344885&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000302%2Fabstract%3Frss%3Dyes Abstract: In this overview we review and model how radiotherapy tumour control and complication rates vary with dose, fractionation, schedule duration, irradiated volume and use of chemotherapy for stage III non-small cell lung cancer (NSCLC), and use the modelling to study the effectiveness of different NSCLC dose-escalation approaches being developed in the UK. Data have been collated for pneumonitis, lung fibrosis, early and late oesophagitis, cord and cardiac complications, and local progression-free survival at 30 months. Dependences of the various end points on treatment-related factors are catalogued and analysed using the linear-quadratic incomplete repair model to account for dose and fractionation effects, making linear corrections for differences in schedule duration, and loosel... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2344885 Mon, 20 Apr 2009 18:40:38 +0100 2344885 http://www.medworm.com/index.php?rid=2344884&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000417%2Fabstract%3Frss%3Dyes Abstract: Aims: To examine the effect of radiotherapy for bone metastases on urinary markers of osteoclast activity.Materials and methods: Patients with radiological evidence of bone metastases planned for palliative radiotherapy were eligible for the study. A urine specimen was collected before and 1 month after radiotherapy to assess levels of calcium, creatinine, magnesium, phosphate, N-telopeptide and pyridinoline. The Brief Pain Inventory was completed in person at baseline and by telephone follow-up at 1 month after radiotherapy. Patients were classified as responders (complete or partial pain response) or non-responders (stable or progressive pain) to radiotherapy based on the International Bone Metastases Consensus Criteria for end point measurements. Absolute values of urine marke... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2344884 Mon, 20 Apr 2009 18:40:37 +0100 2344884 http://www.medworm.com/index.php?rid=2344883&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000296%2Fabstract%3Frss%3Dyes Conclusion: Dexamethasone is effective in the prophylaxis of radiotherapy-induced pain flare after palliative radiotherapy for bone metastases. Randomised studies are needed to confirm this finding. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2344883 Mon, 20 Apr 2009 18:40:36 +0100 2344883 http://www.medworm.com/index.php?rid=2344882&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655508004937%2Fabstract%3Frss%3Dyes Conclusions: There was general support for dose-banding, but concerns about the lack of an evidence base could be a barrier to the wider introduction of the system. Consequently, more clinical studies are required to justify the safety and efficacy of dose-banding, and also to evaluate whether dose-banding is acceptable within clinical trials. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2344882 Mon, 20 Apr 2009 18:40:32 +0100 2344882 http://www.medworm.com/index.php?rid=2344881&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000387%2Fabstract%3Frss%3Dyes Conclusion: This study suggests that radiotherapy is not a risk for SPT induction; it may, however, neutralise a proportion of cancerised fields in the lung and head and neck areas without any significant benefit on overall survival. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2344881 Mon, 20 Apr 2009 18:40:31 +0100 2344881 http://www.medworm.com/index.php?rid=2344880&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000260%2Fabstract%3Frss%3Dyes Conclusions: The activity of ECF in ACC of the head and neck seems to be similar to the combination of cisplatin and 5-fluorouracil and single-agent epirubicin. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2344880 Mon, 20 Apr 2009 18:40:30 +0100 2344880 http://www.medworm.com/index.php?rid=2344879&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000235%2Fabstract%3Frss%3Dyes Building on the success of two previous years , the third National Colorectal Cancer Consensus Meeting was held at the Royal College of Physicians in London on 18 November 2008. More than 200 people attended the meeting, including medical and surgical oncologists (42%), nurses (23%), other healthcare professionals (8%) and patients (11%). (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2344879 Mon, 20 Apr 2009 18:40:29 +0100 2344879 http://www.medworm.com/index.php?rid=2344878&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655508004949%2Fabstract%3Frss%3Dyes Conclusion: We conclude that the homozygous PTGS2 169-GG genotype may be associated with breast cancer risk. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2344878 Mon, 20 Apr 2009 18:40:28 +0100 2344878 http://www.medworm.com/index.php?rid=2344877&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000375%2Fabstract%3Frss%3Dyes Conclusions: The standard radiotherapy tangential technique for breast/chest wall treatments has not significantly changed over many decades, whereas across many other tumour sites there have been great advances in radiotherapy technology. The dosimetric advantages of IMRT are readily apparent from our early experience. The wider spread of the lower dose zone (the low dose ‘bath’ of radiation) is a potential concern regarding late oncogenesis and methods to minimise such risks should be considered. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2344877 Mon, 20 Apr 2009 18:40:26 +0100 2344877 http://www.medworm.com/index.php?rid=2344876&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000430%2Fabstract%3Frss%3Dyes Abstract: With more than 1 million new cases each year, female breast cancer is the second most common cancer in the world and the most common cancer among women. Breast cancer involves a multimodality treatment and a co-ordinated approach from various specialties. Breast-conserving therapy (BCT) is increasingly being integrated into the management of breast cancer. The obvious advantages of BCT are equivalent local and distant control rates as compared with mastectomy and the preservation of the breast. However, the key to a successful BCT is achieving a cosmetic outcome that is acceptable to the patient and the physician. Cosmesis in breast cancer is the end result of a range of factors that fall under the broad heads of surgery, radiotherapy, chemotherapy and hormonal treatment. All of ... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2344876 Mon, 20 Apr 2009 18:40:25 +0100 2344876 http://www.medworm.com/index.php?rid=2344875&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655509000326%2Fabstract%3Frss%3Dyes Despite improvements in recent years, most patients diagnosed with oesophageal cancer present with advanced disease and ultimately die of their malignancy . In the UK, most patients considered suitable for potentially curative therapy are referred to a designated specialist upper gastrointestinal surgeon who, after discussion at a multidisciplinary team meeting, will discuss possible treatment options with the patient. After staging investigations and physiological assessment, only 20–35% of all diagnosed cases will be considered ‘operable’. These patients will usually be offered neoadjuvant chemotherapy followed by surgery, and those with adenocarcinoma may be considered for the Medical Research Council OE05 clinical trial . Most patients who are operated on will die within 2 years ... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2344875 Mon, 20 Apr 2009 18:40:23 +0100 2344875 http://www.medworm.com/index.php?rid=2316984&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19345074%26dopt%3DAbstract CONCLUSION: After curative radiotherapy, all patients presented some radiographic abnormality. There was no correlation with lung symptoms. The assessment of radiation-induced lung toxicity differs depending on the scoring system used. Comparison of reports that use different scoring scales should be made with caution. A scale based on symptoms only, such as the NCI-CTC scale, may be more appropriate to evaluate long-term toxicity after curative radiotherapy for lung cancer. PMID: 19345074 [PubMed - as supplied by publisher] (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2316984 Wed, 01 Apr 2009 04:00:00 +0100 2316984 http://www.medworm.com/index.php?rid=2291808&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19304468%26dopt%3DAbstract Authors: Ghosal N, Misra V PMID: 19304468 [PubMed - as supplied by publisher] (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2291808 Fri, 20 Mar 2009 04:00:00 +0100 2291808 http://www.medworm.com/index.php?rid=2266000&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19282157%26dopt%3DAbstract CONCLUSIONS: This single-centre retrospective study supports the treatment for selected cases of anal canal cancer with smaller than standard radiation fields, avoiding prophylactic inguinal nodal irradiation. Hopefully this will translate into reduced acute and late toxicity. In future studies we would suggest that consideration is given as to whether omission of prophylactic inguinal nodal irradiation for early stage tumours should be explored. PMID: 19282157 [PubMed - as supplied by publisher] (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2266000 Tue, 10 Mar 2009 04:00:00 +0100 2266000 http://www.medworm.com/index.php?rid=2265999&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19282158%26dopt%3DAbstract CONCLUSIONS: Both day-to-day bladder volume variation and bladder filling during treatment should be considered in RTP and delivery. Ultrasound may provide a practical daily verification tool by: supporting volume limitation as a method of treatment margin reduction; allowing detection of patients who may require interventions to promote bladder reproducibility; and identifying patients with prominent volume changes for the selective application of more advanced adaptive/image-guided radiotherapy techniques. PMID: 19282158 [PubMed - as supplied by publisher] (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2265999 Tue, 10 Mar 2009 04:00:00 +0100 2265999 http://www.medworm.com/index.php?rid=2253978&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19269798%26dopt%3DAbstract CONCLUSIONS: Continuous infusional 5-fluorouracil has activity in transitional cell carcinoma of the urinary tract. Prolonged fluoropyrimidine administration may be a useful component of future combination regimens for this disease, particularly in patients with poor renal function. PMID: 19269798 [PubMed - as supplied by publisher] (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2253978 Fri, 06 Mar 2009 05:00:00 +0100 2253978 http://www.medworm.com/index.php?rid=2253980&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19269143%26dopt%3DAbstract Authors: Munshi A PMID: 19269143 [PubMed - as supplied by publisher] (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2253980 Thu, 05 Mar 2009 05:00:00 +0100 2253980 http://www.medworm.com/index.php?rid=2253979&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19269144%26dopt%3DAbstract Authors: Kaur J, Brown KT PMID: 19269144 [PubMed - as supplied by publisher] (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2253979 Thu, 05 Mar 2009 05:00:00 +0100 2253979 http://www.medworm.com/index.php?rid=2253982&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19268554%26dopt%3DAbstract CONCLUSIONS: VMAT is able to boost more of the CTV to >/=120% than cIMRT without contravening OAR dose constraints, and uses 48% fewer monitor units. Treatment times were 61% less than with cIMRT. PMID: 19268554 [PubMed - as supplied by publisher] (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2253982 Wed, 04 Mar 2009 05:00:00 +0100 2253982 http://www.medworm.com/index.php?rid=2253981&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19268555%26dopt%3DAbstract CONCLUSIONS: DCA and SCF are preferred conventional SRT techniques in terms of target conformity and reduction of doses to OARs. The use of IMSRT_NCP further improves conformity and reduces doses to OARs in a range of brain tumours commonly considered for stereotactic irradiation. PMID: 19268555 [PubMed - as supplied by publisher] (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2253981 Wed, 04 Mar 2009 05:00:00 +0100 2253981 http://www.medworm.com/index.php?rid=2249313&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19264466%26dopt%3DAbstract Authors: Chew JS, Saleem M, Florkowski CM, George PM PMID: 19264466 [PubMed - as supplied by publisher] (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2249313 Tue, 03 Mar 2009 05:00:00 +0100 2249313 http://www.medworm.com/index.php?rid=2173045&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19200920%26dopt%3DAbstract Authors: Reed MW, Wyld L, Ellis P, Bliss J, Leonard R, PMID: 19200920 [PubMed - as supplied by publisher] (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2173045 Tue, 10 Feb 2009 18:46:32 +0100 2173045 http://www.medworm.com/index.php?rid=2173043&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19201584%26dopt%3DAbstract CONCLUSIONS: There was general support for dose-banding, but concerns about the lack of an evidence base could be a barrier to the wider introduction of the system. Consequently, more clinical studies are required to justify the safety and efficacy of dose-banding, and also to evaluate whether dose-banding is acceptable within clinical trials. PMID: 19201584 [PubMed - as supplied by publisher] (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2173043 Fri, 06 Feb 2009 05:00:00 +0100 2173043 http://www.medworm.com/index.php?rid=2173042&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19201585%26dopt%3DAbstract CONCLUSIONS: The activity of ECF in ACC of the head and neck seems to be similar to the combination of cisplatin and 5-fluorouracil and single-agent epirubicin. PMID: 19201585 [PubMed - as supplied by publisher] (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2173042 Fri, 06 Feb 2009 05:00:00 +0100 2173042 http://www.medworm.com/index.php?rid=2173044&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19201173%26dopt%3DAbstract Authors: Ghafoor Q, Ford DR, Capaldi L, Heyes GJ, Wyatt RM, Doherty A, El-Modir A PMID: 19201173 [PubMed - as supplied by publisher] (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2173044 Thu, 05 Feb 2009 05:00:00 +0100 2173044 http://www.medworm.com/index.php?rid=2173046&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19200696%26dopt%3DAbstract Authors: Tanaka K, Mohri Y, Nishioka J, Ohi M, Yokoe T, Miki C, Tonouchi H, Nobori T, Kusunoki M PMID: 19200696 [PubMed - as supplied by publisher] (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=2173046 Wed, 04 Feb 2009 05:00:00 +0100 2173046